Monte Rosa Therapeutics (GLUE) Consolidated Net Income: 2023-2025
Historic Consolidated Net Income for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to -$27.1 million.
- Monte Rosa Therapeutics' Consolidated Net Income fell 13.50% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 117.52%. This contributed to the annual value of -$72.7 million for FY2024, which is 46.27% up from last year.
- Per Monte Rosa Therapeutics' latest filing, its Consolidated Net Income stood at -$27.1 million for Q3 2025, which was down 120.26% from -$12.3 million recorded in Q2 2025.
- Monte Rosa Therapeutics' Consolidated Net Income's 5-year high stood at $46.9 million during Q1 2025, with a 5-year trough of -$35.2 million in Q2 2023.
- In the last 3 years, Monte Rosa Therapeutics' Consolidated Net Income had a median value of -$30.3 million in 2024 and averaged -$18.2 million.
- Over the last 5 years, Monte Rosa Therapeutics' Consolidated Net Income had its largest YoY gain of 246.58% in 2025, and its largest YoY loss of 13.50% in 2025.
- Quarterly analysis of 3 years shows Monte Rosa Therapeutics' Consolidated Net Income stood at -$33.3 million in 2023, then spiked by 140.32% to $13.4 million in 2024, then decreased by 13.50% to -$27.1 million in 2025.
- Its last three reported values are -$27.1 million in Q3 2025, -$12.3 million for Q2 2025, and $46.9 million during Q1 2025.